

Kamal S Saini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/622735/publications.pdf>

Version: 2024-02-01

55
papers

2,441
citations

331259

21
h-index

233125

45
g-index

55
all docs

55
docs citations

55
times ranked

5376
citing authors

#	ARTICLE	IF	CITATIONS
1	Manufacture of adoptive cell therapies at academic cancer centers: scientific, safety and regulatory challenges. <i>Annals of Oncology</i> , 2022, 33, 6-12.	0.6	7
2	Immuno-oncology trends: preclinical models, biomarkers, and clinical development. , 2022, 10, e003231.		20
3	Role of decentralized clinical trials in cancer drug development: Results from a survey of oncologists and patients. <i>Digital Health</i> , 2022, 8, 205520762210999.	0.9	5
4	Determining lines of therapy in patients with solid cancers: a proposed new systematic and comprehensive framework. <i>British Journal of Cancer</i> , 2021, 125, 155-163.	2.9	27
5	Mortality in adult patients with solid or hematological cancers and SARS-CoV-2 infection with a specific focus on lung and breast malignancies: A systematic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , 2021, 39, e18608-e18608.	0.8	0
6	Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D). <i>European Journal of Cancer</i> , 2021, 148, 287-296.	1.3	11
7	Emerging issues related to COVID-19 vaccination in patients with cancer. <i>Oncology and Therapy</i> , 2021, , 1-11.	1.0	15
8	Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in breast cancer therapeutics. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 945-962.	1.4	26
9	Mortality in adult patients with solid or hematological malignancies and SARS-CoV-2 infection with a specific focus on lung and breast cancers: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 163, 103365.	2.0	48
10	Cancer Treatment and Research During the COVID-19 Pandemic: Experience of the First 6 Months. <i>Oncology and Therapy</i> , 2020, 8, 171-182.	1.0	24
11	Mortality in patients with cancer and coronavirus disease 2019: A systematic review and pooled analysis of 52 studies. <i>European Journal of Cancer</i> , 2020, 139, 43-50.	1.3	267
12	Reimagining Global Oncology Clinical Trials for the Postpandemic Era: A Call to Arms. <i>JCO Global Oncology</i> , 2020, 6, 1357-1362.	0.8	16
13	Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy. <i>British Journal of Cancer</i> , 2020, 123, 694-697.	2.9	37
14	Effect of the COVID-19 pandemic on cancer treatment and research. <i>Lancet Haematology</i> , the, 2020, 7, e432-e435.	2.2	103
15	Estimating Mortality in Patients with Hematological Malignancy and COVID-19: A Pooled Analysis of 10 Studies. <i>Blood</i> , 2020, 136, 13-14.	0.6	0
16	Galactogram for Investigation of Pathological Nipple Discharge: A Forgotten Arrow in the Radiologists'™ Quiver?. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2018, 39, 96-99.	0.1	1
17	Towards understanding the breast cancer epigenome: a comparison of genome-wide DNA methylation and gene expression data. <i>Oncotarget</i> , 2016, 7, 3002-3017.	0.8	19
18	Treatment of early-stage HER2 breast cancer – an evolving field. <i>Ecancermedalscience</i> , 2015, 9, 523.	0.6	8

#	ARTICLE	IF	CITATIONS
19	Biobanking in the era of precision oncology. Indian Journal of Medical and Paediatric Oncology, 2015, 36, 1.	0.1	4
20	Abstract OT1-1-01: LORELEI: A Phase II randomized, double-blind study of neoadjuvant letrozole plus taselisib (GDC-0032) versus letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative, early stage breast cancer. , 2015, , .		0
21	The AURORA initiative for metastatic breast cancer. British Journal of Cancer, 2014, 111, 1881-1887.	2.9	77
22	Neurofibromatosis type I with breast cancer: not only for women!. Hereditary Cancer in Clinical Practice, 2014, 12, 5.	0.6	12
23	Gastric diffuse large B cell lymphoma presenting as paraneoplastic cerebellar degeneration: Case report and review of literature. Journal of the Egyptian National Cancer Institute, 2013, 25, 231-235.	0.6	6
24	Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer. Cancer Treatment Reviews, 2013, 39, 935-946.	3.4	308
25	Genomic grade adds prognostic value in invasive lobular carcinoma. Annals of Oncology, 2013, 24, 377-384.	0.6	52
26	Magnitude of Trastuzumab Benefit in Patients With HER2-Positive, Invasive Lobular Breast Carcinoma: Results From the HERA Trial. Journal of Clinical Oncology, 2013, 31, 1954-1960.	0.8	39
27	Analysis of Regional Timelines To Set Up a Global Phase III Clinical Trial in Breast Cancer: The Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Experience. Oncologist, 2013, 18, 134-140.	1.9	29
28	Pertuzumab: new hope for patients with HER2-positive breast cancer. Annals of Oncology, 2013, 24, 273-282.	0.6	128
29	Genomic Grade Index (GGI): Feasibility in Routine Practice and Impact on Treatment Decisions in Early Breast Cancer. PLoS ONE, 2013, 8, e66848.	1.1	21
30	Abstract OT2-6-11: PENELOPE: Phase III study evaluating palbociclib (PD-0332991), a cyclin-dependent kinase (CDK) 4/6 inhibitor in patients with hormone-receptor-positive, HER2-normal primary breast cancer with high relapse risk after neoadjuvant chemotherapy (GBG-78/BIG1-13). , 2013, , .		9
31	Challenges in launching multinational oncology clinical trials in India. South Asian Journal of Cancer, 2013, 02, 044-049.	0.2	6
32	Role of the multidisciplinary team in breast cancer management: results from a large international survey involving 39 countries. Annals of Oncology, 2012, 23, 853-859.	0.6	162
33	Targeted therapies in breast cancer: are heart and vessels also being targeted?. Breast Cancer Research, 2012, 14, 209.	2.2	24
34	Dissecting the Heterogeneity of Triple-Negative Breast Cancer. Journal of Clinical Oncology, 2012, 30, 1879-1887.	0.8	388
35	Benefit-Risk Assessment of Bevacizumab in the Treatment of Breast Cancer. Drug Safety, 2012, 35, 15-25.	1.4	12
36	Prevention and management of major side effects of targeted agents in breast cancer. Critical Reviews in Oncology/Hematology, 2012, 84, e79-e85.	2.0	13

#	ARTICLE	IF	CITATIONS
37	Bevacizumab and Breast Cancer: A Meta-Analysis of First-Line Phase III Studies and a Critical Reappraisal of Available Evidence. <i>Journal of Oncology</i> , 2012, 2012, 1-8.	0.6	79
38	Abstract P3-05-03: Characterization of PIK3CA mutations in lobular breast cancer. , 2012, , .		0
39	Rituximab in Hodgkin lymphoma: Is the target always a hit?. <i>Cancer Treatment Reviews</i> , 2011, 37, 385-390.	3.4	38
40	Beyond trastuzumab: New treatment options for HER2-positive breast cancer. <i>Breast</i> , 2011, 20, S20-S27.	0.9	53
41	Integrate: a new model in collaborative breast cancer research. <i>Breast</i> , 2011, 20, S26-S27.	0.9	1
42	DNA methylation profiling reveals a predominant immune component in breast cancers. <i>EMBO Molecular Medicine</i> , 2011, 3, 726-741.	3.3	210
43	OT1-02-04: Adjuvant Pertuzumab and Herceptin IN IniTial TherapY of Breast Cancer: APHINITY (BIG) Tj ETQq1 1 0.784314 rgBT /Overlo		3
44	Abstract LB-180: Epigenetic portraits of human breast cancers. , 2011, , .		0
45	Genomic grade: Feasibility in routine practice and influence on treatment decision in early breast cancer.. <i>Journal of Clinical Oncology</i> , 2011, 29, 606-606.	0.8	15
46	Use of genomic grade index to improve tumor grading of invasive lobular breast carcinoma.. <i>Journal of Clinical Oncology</i> , 2011, 29, 535-535.	0.8	0
47	P1-02-05: Invasive Lobular Carcinoma " A Luminal Breast Cancer Histotype Enriched for Epithelial-to-Mesenchymal Transition Features.. , 2011, , .		0
48	Polycythemia vera-associated pruritus and its management. <i>European Journal of Clinical Investigation</i> , 2010, 40, 828-834.	1.7	61
49	Tamoxifen in early-stage estrogen receptor-positive breast cancer: overview of clinical use and molecular biomarkers for patient selection. <i>OncoTargets and Therapy</i> , 2010, 4, 1.	1.0	29
50	Primary synovial sarcoma of kidney-a report of 2 cases and review of literature. <i>Journal of the Egyptian National Cancer Institute</i> , 2010, 22, 149-53.	0.6	4
51	Blindness as an initial presentation of rectal cancer with brain metastases. <i>Saudi Journal of Gastroenterology</i> , 2009, 15, 63.	0.5	2
52	Orbital metastasis: a rare presentation of osteosarcoma. <i>International Ophthalmology</i> , 2008, 28, 433-436.	0.6	8
53	Skin nodules as a presenting feature of diffuse large B-cell gastric lymphoma. <i>Indian Journal of Dermatology</i> , 2008, 53, 39.	0.1	1
54	Magnetic resonance spectroscopy in pituitary tuberculoma. <i>Singapore Medical Journal</i> , 2007, 48, 783-6.	0.3	8

#	ARTICLE	IF	CITATIONS
55	Simultaneous occurrence of multiple myeloma and acute myeloid leukemia. Turkish Journal of Haematology, 2006, 23, 209-11.	0.2	5